PR Newswire BiotechOriginal article
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
Phase 1positiveTTX-MC138Positive
AI Analysis
Summary
TransCode reports continued disease stabilization with TTX-MC138 in Phase 1a trial follow-up, with 71.4% stable disease rate in 14 efficacy-evaluable patients with advanced solid tumors. Extended treatment duration and disease control through three months demonstrate antitumor activity in heavily pretreated patients.
Clinical Trial Data
Phase
1a
Primary Endpoint
Met
Patients
14
Outcome Details
71.4% stable disease rate, 57.1% disease control through three months, 36.7% maintained disease control
Importance:5/10
Sentiment:
0.70
Phase 1solid tumorsdisease stabilizationclinical trialantitumor activity
Read the original article
Published by PR Newswire Biotech on September 28, 2026 12:04 PM